Biotech entity
pharma is the sole category represented across all 1 tracked stories. Conduit Pharmaceuticals is most often covered alongside CDT Equity Inc. / Conduit Pharmaceuticals, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Conduit Pharmaceuticals, all published on August 10, 2026.
Last mentioned: Aug 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Conduit Pharmaceuticals is most often covered alongside CDT Equity Inc. / Conduit Pharmaceuticals, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Conduit Pharmaceuticals, all published on August 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Conduit Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Source: themarketsdaily.com · tickerreport.com
Conduit Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
